Atazanavir CAS 198904-31-3 Purity ≥99.0% API Factory Anti-HIV HIV-1 Protease Inhibitor

Atazanavir (CAS 198904-31-3) is an antiretroviral, novel and potent azapeptide drug of the protease inhibitor (PI) class. It is sold under the trade name Reyataz. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus type 1 (HIV-1) protease enzyme with inhibition constant Ki of 66 nmol/L and also inhibits the viral replication of HIV-1 with 50% effective concentration EC50 ranging from 2.6 to 5.3 nmol/L. Atazanavir binds to HIV-1 protease preventing the cleavage of gag and gag-pol polyproteins, which results in the formation of immature virions in HIV-1-infected cells. Atazanavir has a different C-2 symmetric chemical structure and a generally greater antiretroviral potency in various HIV strains compared to other protease inhibitors, including Indinavir, Nelfinavir, Ritonavir, Saquinavir and Amprenavir. Atazanavir is distinguished from other PIs in that it can be given once-daily and has lesser effects on the patient's lipid profile. Like other protease inhibitors, it is used only in combination with other HIV medications. Atazanavir is a novel azapeptide HIV protease inhibitor. Antiviral. It is taken by mouth once a day.